CaltechAUTHORS
  A Caltech Library Service

The promoter of the human interleukin-2 gene contains two octamer-binding sites and is partially activated by the expression of Oct-2

Kamps, Mark P. and Corcoran, Lynn and LeBowitz, Jonathan H. and Baltimore, David (1990) The promoter of the human interleukin-2 gene contains two octamer-binding sites and is partially activated by the expression of Oct-2. Molecular and Cellular Biology, 10 (10). pp. 5464-5472. ISSN 0270-7306. http://resolver.caltech.edu/CaltechAUTHORS:KAMmcb90

[img]
Preview
PDF
See Usage Policy.

2041Kb

Use this Persistent URL to link to this item: http://resolver.caltech.edu/CaltechAUTHORS:KAMmcb90

Abstract

The gene encoding interleukin-2 (IL-2) contains a sequence 52 to 326 nucleotides upstream of its transcriptional initiation site that promotes transcription in T cells that have been activated by costimulation with tetradecanoyl phorbol myristyl acetate (TPA) and phytohemagglutinin (PHA). We found that the ubiquitous transcription factor, Oct-1, bound to two previously identified motifs within the human IL-2 enhancer, centered at nucleotides -74 and -251. Each site in the IL-2 enhancer that bound Oct-1 in vitro was also required to achieve a maximal transcriptional response to TPA plus PHA in vivo. Point mutations within either the proximal or distal octamer sequences reduced the response of the enhancer to activation by 54 and 34%, respectively. Because the murine T-cell line EL4 constitutively expresses Oct-2 and requires only TPA to induce transcription of the IL-2 gene, the effect of Oct-2 expression on activation of the IL-2 promoter in Jurkat T cells was determined. Expression of Oct-2 potentiated transcription 13-fold in response to TPA plus PHA and permitted the enhancer to respond to the single stimulus of TPA. Therefore, both the signal requirements and the magnitude of the transcription response of the IL-2 promoter can be modulated by Oct-2.


Item Type:Article
Additional Information:Copyright © 1990 by the American Society for Microbiology. Received 7 March 1990/Accepted 15 June 1990 Mark Kamps is supported by The Damon Runyon-Walter Winchell Cancer Research Fund, grant DRG982, and Lynn Corcoran is supported by The Life Sciences Research Foundation. Jonathan LeBowitz is a Special Fellow of The Leukemia Society of America. This work was funded by Public Health Service grant GM 39458 from the National Institutes of Health.
Record Number:CaltechAUTHORS:KAMmcb90
Persistent URL:http://resolver.caltech.edu/CaltechAUTHORS:KAMmcb90
Alternative URL:http://mcb.asm.org/cgi/content/abstract/10/10/5464
Usage Policy:No commercial reproduction, distribution, display or performance rights in this work are provided.
ID Code:8733
Collection:CaltechAUTHORS
Deposited By: Archive Administrator
Deposited On:11 Sep 2007
Last Modified:26 Dec 2012 09:41

Repository Staff Only: item control page